Abstract:Matrix metalloproteinase-9 (MMP-9) has been considered as an attractive target involving cancer therapy. In this study, the 3D QSAR pharmacophore model of MMP-9 inhibitors is built, and its reliability is subsequently validated based on different methods. The built pharmacophore model consists of the four chemical features, including two hydrogen bond acceptors (HBA), one hydrophobic (HY), and one ring aromatic (RA). Among them, both HY and RA are found to be especially important features because they involve the interactions of inhibitors with the S1' pocket of MMP-9, which determines the selectivity of MMP-9 inhibitors. By combining pharmacophore model with molecular docking, the virtual screening is carried out to identify the selective MMP-9 inhibitors from natural products. The four potential selective MMP-9 inhibitors of natural products are found. One of them was used to carry out the bioassay experiment inhibiting MMP-9, and the estimated IC<sub>50</sub> value of only 26.94 µM clearly shows its strongly inhibitory activity; besides, both the hybrid quantum mechanics/molecular mechanics (QM/MM) calculation and the molecular dynamics simulation are performed to examine the reliability regarding the binding mode of this inhibitor with MMP-9 active sites predicted by molecular docking. All the screened four natural products are found to well bind with the MMP-9 active sites by different kinds of interactions. Finally, the ADMET properties of screened four natural products are assessed. These screened MMP-9 inhibitors of natural products could be used as the lead compounds to perform structural modifications and optimizations in the future work. Communicated by Ramaswamy H. Sarma.

Synthesis of Derivatives of Methyl Rosmarinate and Their Inhibitory Activities Against Matrix Metalloproteinase-1 (MMP-1)

[Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].

Sulfonamide Derivatives Containing Dihydropyrazole Moieties Selectively and Potently Inhibit Mmp-2/Mmp-9: Design, Synthesis, Inhibitory Activity and 3D-Qsar Analysis

Design, Synthesis and Preliminary Evaluation of Α-Sulfonyl Γ-(Glycinyl-amino)proline Peptidomimetics As Matrix Metalloproteinase Inhibitors.

Design, Synthesis and Preliminary Evaluation of Novel Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors

Synthesis of New Sulfonyl Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors

Design, Synthesis, and Biological Evaluation of 4-Phenoxybenzenesulfonyl Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors

Design, Synthesis, and Primary Activity Evaluation of Pyrrolidine Derivatives As Matrix Metalloproteinase Inhibitors.

Multiple Receptor-Ligand Based Pharmacophore Modeling and Molecular Docking to Screen the Selective Inhibitors of Matrix Metalloproteinase-9 from Natural Products.

In Silico Study Combining Docking and QSAR Methods on a Series of Matrix Metalloproteinase 13 Inhibitors.

A Combined Molecular Modeling Study on Gelatinases and Their Potent Inhibitors

Comfa/Comsia and Molecular Docking Studies of Novel Matrix Metalloproteinase-2 Inhibitors Based on L-Tyrosine Scaffold

Natural products as a gold mine for selective matrix metalloproteinases inhibitors.

Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation

Sulfonyl Phosphonic 1,4-Dithia-7-azaspiro[4,4]nonane Derivatives As Matrix Metalloproteinase Inhibitors: Synthesis, a Docking Study, and Biological Evaluation.

Design, Synthesis, Evaluation and 3D-QSAR Analysis of Benzosulfonamide Benzenesulfonates As Potent and Selective Inhibitors of MMP-2

Dihydropyrazothiazole Derivatives As Potential MMP-2/MMP-8 Inhibitors for Cancer Therapy.

Theoretical Studies on the Potency of Novel Matrix Metalloproteinases Inhibitors

Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.

Synthesis and Biological Evaluation of Novel Benzofuroxan-Based Pyrrolidine Hydroxamates As Matrix Metalloproteinase Inhibitors with Nitric Oxide Releasing Activity.

Nitro-based selective inhibitors against matrix metalloproteinase-7 over matrix metalloproteinase-1